Parabilis now the largest VC-backed biotech IPO
Parabilis Medicines’ $745M IPO redefines biotech funding—now the largest VC-backed debut in history.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Parabilis Medicines has completed its initial public offering (IPO) on NASDAQ, raising $745 million after upsizing its deal. The company’s shares surged 67% on debut, propelling its market capitalization to $3.7 billion—the largest VC-backed biotech IPO to date. Coverage highlights its focus on targeting previously 'undruggable' diseases, positioning it as a leader in high-risk, high-reward drug development.
Financial and biotech media outlets, including Bloomberg, WSJ, and BioSpace, emphasize the IPO’s record-breaking valuation and the broader market signal it sends. The surge follows a trend of high-profile biotech IPOs, though analysts note the optimism is concentrated in companies with reduced development risk. Watch for investor reactions to Parabilis’ pipeline progress and whether its success spurs more VC-backed biotechs to pursue IPOs.
Coverage also suggests scrutiny of whether the market can sustain valuations for early-stage biotech firms beyond the 'derisked' subset.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (88% supported) Updated 88d ago.
Quick answers
What is Parabilis Medicines’ market cap after its IPO?
Parabilis Medicines’ market cap reached $3.7 billion following its first day of trading on NASDAQ.
How much did Parabilis raise in its IPO?
Parabilis raised $745 million after upsizing its initial public offering.
What distinguishes Parabilis from other biotech IPOs?
Parabilis is noted for targeting 'undruggable' diseases and has become the largest VC-backed biotech IPO to date, signaling confidence in its high-risk, high-reward approach.
Coverage (10)
- 'Going for our own moonshot': Parabilis CEO on biotech's record IPO Endpoints News · 91d ago
- Parabilis Medicines Rings the Closing Bell Nasdaq · 91d ago
- Drugmaker Parabilis Soars 67% After $745 Million IPO, Placement Bloomberg.com · 91d ago
- Parabilis soars to $3.7B market cap after first day on NASDAQ FirstWord Pharma · 91d ago
- Parabilis Medicines Shares Rocket Following Record Biotech IPO WSJ · 91d ago
- Parabilis Medicines’ Quest to Drug the Undruggable Picks Up $745M From Upsized IPO MedCity News · 91d ago
- Sky-high Parabilis, Kailera IPOs spur optimism—but only for derisked biotechs BioSpace · 91d ago
- Parabilis Medicines Announces Pricing of Upsized Initial Public Offering Stock Titan · 91d ago
- Parabilis sets a record with a $670M biotech IPO BioPharma Dive · 91d ago
- Parabilis now the largest VC-backed biotech IPO Yahoo Finance · 91d ago
Topics
Related trends
Shopify acquires Tailwind Labs (SHOP:NASDAQ)
Shopify has acquired Tailwind Labs to accelerate its push into custom storefront development and enhance its e-commerce ecosystem.
Dow tumbles 400 points, posting 3-day slide as rates jump and Brent crude tops $101: Live updates
Financial markets extend a losing streak as major stock indexes fall, treasury yields rise, and oil prices cross notable thresholds.
Chime Financial Signals Breakout On Strong Guidance, Key Acquisition
Chime Financial announces an agreement to acquire Stride Bank in a cash transaction valued at 590 million dollars.
Micron Stock Pops on Fresh Memory-Chip Price Data
Micron stock draws widespread market attention amid new financial forecasts and memory-chip data.
Adobe's Next Earnings Report on Sept. 10 Could Send the Stock Plunging. Here's Why.
Investors are bracing for Adobe's Q3 earnings report on September 10, with analysts debating whether the stock will plunge or climb toward $300.
Nvidia Is No Longer Just a Chip Company. It’s the Infrastructure Platform for All of AI
Market coverage reveals Nvidia shifting from a pure chipmaker to the foundational infrastructure platform for all of artificial intelligence.